BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36329397)

  • 1. Identifying optimal candidates for postoperative adjuvant therapy among regional persistent/recurrent nasopharyngeal carcinoma patients after neck dissection.
    Liu SL; Li XY; Sun XS; Peng JY; Lin C; Yan JJ; Chen QY; Tang LQ; Guo SS; Guo L; Liu LT; Mai HQ
    BMC Cancer; 2022 Nov; 22(1):1129. PubMed ID: 36329397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
    Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
    Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgery for isolated regional failure in nasopharyngeal carcinoma after radiation: Selective or comprehensive neck dissection.
    Liu YP; Li H; You R; Li JB; Liu XK; Yang AK; Guo X; Song M; Zhang Q; Guo ZM; Chen WK; Liu WW; Zou X; Hua YJ; Yang Q; Zhang YN; Sun R; Mo HY; Guo L; Lin AH; Mai HQ; Qian CN; Chen MY
    Laryngoscope; 2019 Feb; 129(2):387-395. PubMed ID: 30325027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
    Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
    Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
    Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
    Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.
    Liu MZ; Fang SG; Huang W; Wang HY; Tian YM; Huang RD; Sun Z; Zhao C; Lu TX; Huang Y; Han F
    Cancer Med; 2019 Aug; 8(10):4633-4643. PubMed ID: 31268626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
    Zhang L; Tang LQ; Chen QY; Liu H; Guo SS; Liu LT; Guo L; Mo HY; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Shao JY; Sun Y; Ma J; Hong MH; Mai HQ
    Oncotarget; 2016 Feb; 7(5):6221-30. PubMed ID: 26716900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of EBV DNA and platelet-to-lymphocyte ratio in patients with non-metastatic nasopharyngeal carcinoma: a retrospective study.
    Dong H; Huang Z; Yang D; Li Z; Huang H; Meng Z; Qin Y; Kang M
    BMC Cancer; 2023 Jul; 23(1):673. PubMed ID: 37464319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic changes in plasma Epstein-Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study.
    He SS; Wang Y; Bao Y; Cai XY; Yang XL; Chen DM; Chen Y; Lu LX
    Cancer Med; 2018 Apr; 7(4):1110-1117. PubMed ID: 29493874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic effect of residual plasma Epstein-Barr viral DNA after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Zheng H; Zhou P; Wang J; Yu YF; Zhou R; Lin Q; Wu SG
    Cancer Med; 2023 Jul; 12(14):14979-14987. PubMed ID: 37212447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of AKR1C4 and the advantage of combining EBV DNA to stratify patients at high risk of locoregional recurrence of nasopharyngeal carcinoma.
    Guo SS; Chen YZ; Liu LT; Liu RP; Liang YJ; Wen DX; Jin J; Tang LQ; Mai HQ; Chen QY
    BMC Cancer; 2022 Aug; 22(1):880. PubMed ID: 35953777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study.
    Lv JW; Chen YP; Zhou GQ; Tang LL; Mao YP; Li WF; Guo R; Lin AH; Ma J; Sun Y
    Oncotarget; 2016 Mar; 7(13):16806-17. PubMed ID: 26919237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
    Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
    Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis.
    Zhang Y; Tang LL; Li YQ; Liu X; Liu Q; Ma J
    Int J Cancer; 2019 May; 144(9):2313-2319. PubMed ID: 30485420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study.
    Du YY; Luo DH; Sun XS; Tang LQ; Mai HQ; Chen QY; Zhong JH; Mai DM; Zhang WR; Chen WH; Mo HY
    Cancer Med; 2019 Nov; 8(16):6841-6852. PubMed ID: 31513364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.
    Li W; Chen J; Liang B; Li Z; Li J; Yuan X; Wu S; Zeng F; Peng X; Li Y; Lu J; Zhao F; Liu X
    Cancer Med; 2021 Feb; 10(3):883-894. PubMed ID: 33378109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying optimal candidates for induction chemotherapy among stage II-IVa nasopharyngeal carcinoma based on pretreatment Epstein-Barr virus DNA and nodal maximal standard uptake values of [
    Xie HJ; Yu YF; Sun XS; Jia GD; Luo DH; Sun R; Liu LT; Guo SS; Liu SL; Chen QY; Tang LQ; Mai HQ
    Cancer Med; 2020 Dec; 9(23):8852-8863. PubMed ID: 33034945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of Epstein-Barr virus DNA load in nasopharyngeal carcinoma: a meta-analysis.
    Alami IE; Gihbid A; Charoute H; Khaali W; Brahim SM; Tawfiq N; Cadi R; Belghmi K; El Mzibri M; Khyatti M
    Pan Afr Med J; 2022; 41():6. PubMed ID: 35145598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of the lymph node-to-primary tumor ratio of PET standardized uptake value and circulating Epstein-Barr virus DNA to predict distant metastasis in nasopharyngeal carcinoma.
    Shen EY; Hung TM; Tsan DL; Cheng NM; Kang CJ; Huang SF; Hsu CL; Lin CY; Wang HM; Hsieh JC; Cheng AJ; Fan KH; Chang JT
    Radiother Oncol; 2022 Dec; 177():1-8. PubMed ID: 35568282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.